BMJ Open:过敏性鼻炎对儿童日常生活的影响

2021-02-20 MedSci原创 MedSci原创

最近,有研究人员进行了横断面观察性调查,阐述了过敏性鼻炎(AR)对澳大利亚儿童(2至15岁)的影响。

  最近,有研究人员进行了横断面观察性调查,阐述了过敏性鼻炎(AR)对澳大利亚儿童(2至15岁)的影响

 

 

 

 

  

  

  研究包括了1541名参与者。研究发现,大部分的AR病例接受了治疗(730/797;90.3%),且可分类为中重度、间歇性AR(549/797;68.9%)。一半的参与者报告在治疗的2周内,症状得到了充分的控制(389/797;48.8%;OR=4.04;95%CI 2.24-7.31)。另外,与没有AR的儿童相比,有AR的儿童与更差的整体健康状况(7.4 vs 8.4,均差(最小二乘平均差异(LSMD))=-0.99;95%CI -1.18--0.79)、更少的快乐天数(22.2 vs 25.9,LSMD=-3. 68;95%CI -4.82--2.54),更多的身体(2.82 vs 0.78,LSMD=2.04;95%CI 1.61-2.47)和情绪(2.14 vs 0.67,LSMD=1.47;95%CI 1.02--1.92)不佳的天数有关。在报告症状控制不足的儿童中,所有这些结果都显著更差(P<0.05)。此外,AR对功课、睡眠和其他活动均能产生负面影响,并增加了患有合并症的可能性。

 

 

 

  

  最后,研究人员指出,澳大利亚儿童家长认为AR的负担很重,它影响到日常生活的许多方面症状控制不足是造成这种影响程度的一个关键因素。因此,优化儿童AR治疗中应包括采用自我评估工具来衡量和监测症状控制是否充分

 

原始出处:

 

  Sinthia Bosnic-Anticevich, Peter Smith, Michael Abramson et al. Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study. BMJ Open. 2020

 



版权声明:


  本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849190, encodeId=00a4184919033, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Mar 22 09:06:30 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728830, encodeId=e4f01e28830ab, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Feb 01 21:06:30 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047374, encodeId=17ec204e37417, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 30 11:06:30 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-03-22 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849190, encodeId=00a4184919033, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Mar 22 09:06:30 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728830, encodeId=e4f01e28830ab, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Feb 01 21:06:30 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047374, encodeId=17ec204e37417, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 30 11:06:30 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2022-02-01 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849190, encodeId=00a4184919033, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Mar 22 09:06:30 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728830, encodeId=e4f01e28830ab, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Feb 01 21:06:30 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047374, encodeId=17ec204e37417, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 30 11:06:30 CST 2021, time=2021-09-30, status=1, ipAttribution=)]